Search
Managlinat dialanetil
go.drugbank.com/drugs/DB05518InvestigationalCS-917 is a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting enzymes of gluconeogenesis.
Tipifarnib
go.drugbank.com/drugs/DB04960InvestigationalIn June 2005, the FDA issued a Not Approvable Letter for Zarnestra.
Categories: P-glycoprotein inhibitorsAfimoxifene
go.drugbank.com/drugs/DB04468InvestigationalAfimoxifene (4-Hydroxytamoxifen, trade name TamoGel) is a new estrogen inhibitor under investigation for a variety of estrogen-dependent conditions, including cyclic breast pain and gynecomastia.
Categories: Estrogen Receptor Modulators, Selective Estrogen Receptor ModulatorsNGN-101
go.drugbank.com/drugs/DB18335InvestigationalNGN-101 is an adeno-associated virus serotype 9 vector with engineered transgene encoding the human CLN5 gene
ECT204
go.drugbank.com/drugs/DB18605InvestigationalECT204 is an autologous T-cell therapy whereby T cells are genetically modified to target tumor-specific antigens.
Trotabresib
go.drugbank.com/drugs/DB17421InvestigationalTrotabresib is an oral, potent, and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.
Sparsomycin
go.drugbank.com/drugs/DB04222ExperimentalAn antitumor antibiotic produced by Streptomyces sparsogenes. It inhibits protein synthesis in 70S and 80S ribosomal systems. [PubChem]
Zalutumumab
go.drugbank.com/drugs/DB12202InvestigationalZalutumumab has been investigated for the treatment of Squamous Cell Cancer and Head and Neck Cancer. … Zalutumumab is a fully human IgG1 monoclonal antibody designed to bind with selectivity to the epidermal growth factor receptor (EGFR).
Zirconium panitumumab Zr-89
go.drugbank.com/drugs/DB19228InvestigationalZirconium panitumumab Zr-89 is under investigation in clinical trial NCT05423197 (Study Evaluating Zr-panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous
Inarigivir soproxil
go.drugbank.com/drugs/DB15063InvestigationalInarigivir soproxil is under investigation in clinical trial NCT03434353 (Study to Evaluate the Antiviral Activity of Inarigivir (GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic